In Silico Identification of Dysregulated miRNAs Targeting KRAS Gene in Pancreatic Cancer

被引:0
|
作者
Garibaldi-Rios, Asbiel Felipe [1 ,2 ]
Figuera, Luis E. [1 ,2 ]
Zuniga-Gonzalez, Guillermo Moises [3 ]
Gomez-Meda, Belinda Claudia [4 ]
Garcia-Verdin, Patricia Montserrat [1 ,2 ]
Carrillo-Davila, Irving Alejandro [1 ,2 ]
Gutierrez-Hurtado, Itzae Adonai [4 ]
Torres-Mendoza, Blanca Miriam [5 ,6 ]
Gallegos-Arreola, Martha Patricia [1 ]
机构
[1] Inst Mexicano Seguro Social IMSS, Div Genet, Ctr Invest Biomed Occidente CIBO, Ctr Med Nacl Occidente CMNO, Guadalajara 44340, Jalisco, Mexico
[2] Univ Guadalajara UdeG, Ctr Univ Ciencias Salud CUCS, Doctorado Genet Humana, Guadalajara 44340, Jalisco, Mexico
[3] Inst Mexicano Seguro Social IMSS, Div Med Mol, Ctr Invest Biomed Occidente CIBO, Ctr Med Nacl Occidente CMNO, Sierra Mojada 800, Guadalajara 44340, Jalisco, Mexico
[4] Univ Guadalajara UdeG, Ctr Univ Ciencias Salud CUCS, Dept Biol Mol & Genom, Inst Genet Humana Dr Enr Corona Rivera, Guadalajara 44340, Jalisco, Mexico
[5] Inst Mexicano Seguro Social IMSS, Lab Inmunodeficiencias Humanas & Retrovirus, Div Neurociencias, Ctr Invest Biomed Occidente CIBO, Guadalajara 44340, Jalisco, Mexico
[6] Univ Guadalajara UdeG, Ctr Univ Ciencias Salud CUCS, Dept Disciplinas Filosof Metodologicas, Guadalajara 44340, Jalisco, Mexico
关键词
pancreatic neoplasms; KRAS proto-oncogene; microRNAs; biomarkers; in silico techniques; gene expression regulation; MICRORNA-BINDING SITE; LUNG-CANCER; RS712; POLYMORPHISM; EXPRESSION; ASSOCIATION; CARCINOMA; MIR-30A-5P; RISK; PROLIFERATION; RS61764370;
D O I
10.3390/diseases12070152
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pancreatic cancer (PC) is highly lethal, with KRAS mutations in up to 95% of cases. miRNAs inversely correlate with KRAS expression, indicating potential as biomarkers. This study identified miRNAs targeting KRAS and their impact on PC characteristics using in silico methods. dbDEMC identified dysregulated miRNAs in PC; TargetScan, miRDB, and PolymiRTS 3.0 identified miRNAs specific for the KRAS gene; and OncomiR evaluated the association of miRNAs with clinical characteristics and survival in PC. The correlation between miRNAs and KRAS was analysed using ENCORI/starBase. A total of 210 deregulated miRNAs were identified in PC (116 overexpressed and 94 underexpressed). In total, 16 of them were involved in the regulation of KRAS expression and 9 of these (hsa-miR-222-3p, hsa-miR-30a-5p, hsa-miR-30b-5p, hsa-miR-30e-5p, hsa-miR-377-3p, hsa-miR-495-3p, hsa-miR-654-3p, hsa-miR-877-5p and hsa-miR-885-5p) were associated with the clinical characteristics of the PC. Specifically, the overexpression of hsa-miR-30a-5p was associated with PC mortality, and hsa-miR-30b-5p, hsa-miR-377-3p, hsa-miR-495-3p, and hsa-miR-885-5p were associated with survival. Correlation analysis revealed that the expression of 10 miRNAs is correlated with KRAS expression. The dysregulated miRNAs identified in PC may regulate KRAS and some are associated with clinically relevant features, highlighting their potential as biomarkers and therapeutic targets in PC treatment. However, experimental validation is required for confirmation.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Therapeutic targeting of oncogenic KRAS in pancreatic cancer by engineered exosomes
    Whiteside, Theresa L.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S1406 - S1408
  • [22] Dysregulated microRNAs (miRNAs) control kallikrein (KLK) gene expression in ovarian cancer
    Diamandis, M.
    Chow, T. -F. F.
    Rofael, Y.
    White, N. M. A.
    Faragalla, H.
    Mankaruous, M.
    Girgis, A.
    Yousef, G. M.
    CLINICAL BIOCHEMISTRY, 2010, 43 (09) : 787 - 787
  • [23] Identification of dysregulated pathways associated with pancreatic cancer by survival analysis
    Yuan, Qiong-Ying
    Gu, Yan-Ping
    Wang, Cong-Jun
    Zhang, Hui
    Wang, Xing-Peng
    MOLECULAR MEDICINE REPORTS, 2015, 11 (01) : 277 - 282
  • [24] Identification and gene expression analysis of circulating tumor cells with high expression of KRAS in pancreatic cancer
    Zheng, Zhiqiang
    Chen, Zhichao
    Lin, Yonghua
    Wei, Jianfeng
    AIP ADVANCES, 2023, 13 (09)
  • [25] In silico identification of miRNAs associated with AMD
    Meester, Magda A.
    Ghanbari, Mohsen
    Colijn, Johanna Maria
    Erkeland, Stefan
    Dehghan, Abbas
    Klaver, Caroline C. W.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [26] Identification and Evaluation in silico and in vitro of Small Molecules in the KRas4B-PDEδ Molecular Complex in Pancreatic Cancer
    Casique Aguirre, Diana
    Garcia Gutierrez, Ponciano
    de Leon Bautista, Mercedes Piedad
    Vargas Mejia, Miguel Angel
    FASEB JOURNAL, 2016, 30
  • [27] Identification of dysregulated miRNAs in triple negative breast cancer: A meta-analysis approach
    Naorem, Leimarembi Devi
    Muthaiyan, Mathavan
    Venkatesan, Amouda
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (07) : 11768 - 11776
  • [28] MiRNAs directly targeting the key intermediates of biological pathways in pancreatic cancer
    Sarwar, Ammar
    Wang, Bo
    Su, Qi
    Zhang, Yanmin
    BIOCHEMICAL PHARMACOLOGY, 2021, 189
  • [29] Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
    Bournet, Barbara
    Buscail, Camille
    Muscari, Fabrice
    Cordelier, Pierre
    Buscail, Louis
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : 75 - 83
  • [30] Targeting KRAS-regulated metabolic activities in pancreatic cancer.
    Bryant, Kirsten L.
    Hobbs, G. Aaron
    Der, Channing J.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 21 - 22